Skip to main content
GoodMoatv1.3
Sign in
CORT logo

CORT

CompareEarnings: Aug 31, 2026

Corcept Therapeutics Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.

Did you know?

Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.

Current Price

$51.42

+10.53%

GoodMoat Value

$16.61

67.7% overvalued
Profile
Valuation (TTM)
Market Cap$5.47B
P/E117.20
EV—
P/B8.44
Shares Out106.37M
P/Sales7.11
Revenue$769.10M
EV/EBITDA—

Corcept Therapeutics Inc (CORT) Company Profile

CORT Company Information

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.

Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.

In February 2012, the company introduced Korlym ®, the first medication approved by the U. S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism.

Corcept is headquartered in Redwood City, California.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

California, USA

CORT Key Officers

Key officers data coming soon

CORT Company Profile

Corcept Therapeutics Inc (CORT) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in California, USA.

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.

Market cap is $5.47B. There are 106.4M shares outstanding.

See the full Corcept Therapeutics Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if CORT is a good investment.